Anti-PD1 following Ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rha

[D.ap]

Anti-PD1 following Ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006358/

[Bonni Hess]

Dear Debbie, As always, I am so deeply grateful for your thoughtful sharing of very important and relevant information. This article highlights for me the recently published very valid concerns regarding the potential for very serious and acute effects associated with PDL-1 Immunotherapy treatments, and is an issue which needs to be thoroughly researched, addressed, and discussed by all of the patients considering Immunotherapy treatment or currently being treated with it. With deepest gratitude for your invaluable sharing, and with increased awareness and concerns regarding PDL-1 Immunotherapy treatment, but still holding very tight to continued Hope for its safety and success for ASPS patients, Bonni